阿斯利康回应在中国面临最新罚款

Core Viewpoint - AstraZeneca is facing potential fines in China related to alleged tax evasion, with the amount in question exceeding $1.6 million [1] Group 1: Legal and Financial Implications - The Shenzhen Customs Anti-Smuggling Bureau issued a notice indicating that AstraZeneca is suspected of evading import taxes [1] - The tax in question is related to the drug Enhertu (deruxtecan) [1] - If AstraZeneca is found liable, it may face penalties ranging from one to five times the unpaid import tax, with a maximum potential fine of $8 million [1]